Please login to the form below

Not currently logged in
Email:
Password:

Dr Véronique Walsh joins BMS UK

Bristol-Myers Squibb UK has appointed Dr Véronique Walsh to the role of business unit director, neuroscience and immunoscience
Bristol-Myers Squibb (BMS) UK has appointed Dr Véronique Walsh to the role of business unit director, neuroscience and immunoscience. She will report to vice president and general manager of BMS UK, Amadou Diarra.

Dr Véronique Walsh, Bristol-Myers Squibb UK
Dr Véronique Walsh


Dr Walsh will lead the sales and marketing teams for BMS' neuroscience and immunoscience portfolio which includes Orencia (abatacept), Abilify (aripiprazole) and Perfalgan (paracetamol IV), as well as investigational products.

Most recently serving as deputy managing director at Sanofi Pasteur MSD UK, and in charge of market access, public affairs, communications, and strategic planning, Dr Walsh has 20 years experience in the vaccines industry. Key achievements during her 14 years at Sanofi Pasteur MSD include the launch of several new vaccines and the development and implementation of market access strategies within the company. 


Before joining the pharmaceutical industry in 1990, Dr Walsh held different hospital and primary care positions in France. She has an MBA from the Business School in Lyon, France, and has completed the Runge Balliol leadership in management course at Oxford. In 2010, she also gained a post graduate certificate in health economics for health professionals from the University of York. 

5th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics